RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9094
-0.0796 (-8.05%)
At close: May 29, 2026, 4:00 PM EDT
0.9055
-0.0039 (-0.43%)
After-hours: May 29, 2026, 7:35 PM EDT
RenovoRx Employees
RenovoRx had 17 employees as of December 31, 2025. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$87,588
Profits / Employee
-$721,706
Market Cap
40.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 7 | 70.00% |
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Mar 31, 2024 | 10 | 0 | - |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Sep 30, 2023 | 10 | 0 | - |
| Jun 30, 2023 | 10 | 0 | - |
| Mar 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Sep 30, 2022 | 10 | 0 | - |
| Jun 30, 2022 | 10 | 2 | 25.00% |
| Mar 31, 2022 | 10 | 4 | 66.67% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Sep 30, 2021 | 10 | 1 | 11.11% |
| Jun 30, 2021 | 8 | - | - |
| Mar 31, 2021 | 6 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| aTyr Pharma | 60 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
| Atossa Therapeutics | 16 |
| Lantern Pharma | 16 |
| Nutriband | 13 |
RNXT News
- 1 day ago - RenovoRx announces FDA Orphan Drug Designation for oxaliplatin - TheFly
- 1 day ago - RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 3 days ago - RenovoRx announces pharmacokinetic data using TAMP platform - TheFly
- 3 days ago - RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 9 days ago - RenovoRx Transcript: A.G.P.'s Annual Virtual Healthcare Conference - Transcripts
- 10 days ago - RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th - GlobeNewsWire
- 15 days ago - RenovoRx reports Q1 adjusted EPS (8c), consensus (8c) - TheFly
- 15 days ago - RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M - TheFly